Organization | Navrongo Health Research Centre, Ghana

Navrongo Health Research Centre, Ghana Report issue

Academic/Hospital Phase 4

Founded: Navrongo Ghana (1992)

Organization Overview

First Clinical Trial

2000

NCT00857077

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Now

Alternative names

Navrongo Health Research Center | Navrongo Health Research Centre, Navrongo, Ghana.

Active Ingredients

Drugs in Phase 4 Trials (8)

albendazole (Albenza) (1 trial)

attenuated measles vaccine (rubeovax) (2 trials)

coartem (2 trials)

human rotavirus, live attenuated (Rotarix) (1 trial)

lumefantrine (Coartem) (2 trials)

praziquantel (biltricide) (1 trial)

pyrimethamine (daraprim) (2 trials)

sulfadoxine (2 trials)

Drugs in Other Trials (2)

acetaminophen (tylenol) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Gastroenteritis (Phase 4)

Helminthiasis (Phase 4)

Malaria (Phase 4)

Measles (Phase 4)

Schistosomiasis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 10